2020-22142. Investigational COVID-19 Convalescent Plasma; Guidance for Industry; Withdrawal of Guidance; Correction
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; correction.
SUMMARY:
The Food and Drug Administration (FDA) is correcting a notice that published in the Federal Register of September 21, 2020. The document announced the withdrawal of a final guidance for industry entitled “Investigational COVID-19 Convalescent Plasma,” which was issued in April 2020 and updated in May 2020. FDA withdrew the guidance because the Agency issued a new guidance for industry of the same title. The document was published with the incorrect docket number for the guidance for industry that was withdrawn. This document corrects that error.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Shruti Modi, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Correction
In the Federal Register of September 18, 2020 (85 FR 593120), appearing on page 59320 in FR Doc. 2020-20801, the following correction is made:
On page 59320, in the third column, the Docket No. “FDA-2020-D-1825” is corrected to read “FDA-2020-D-1137.”
Start SignatureDated: October 1, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2020-22142 Filed 10-6-20; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Published:
- 10/07/2020
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice; correction.
- Document Number:
- 2020-22142
- Pages:
- 63277-63277 (1 pages)
- Docket Numbers:
- Docket No. FDA-2020-D-1137
- PDF File:
- 2020-22142.pdf
- Supporting Documents:
- » Guidance Documents Related to Coronavirus Disease 2019; Availability
- » Emergency Use Authorization for Vaccines to Prevent COVID-19
- » Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing - Guidance for Industry - June 2020
- » Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency Guidance for Industry
- » Reference 23 re Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry
- » Reference 19 re Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry
- » Reference 18 re Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry
- » Reference 15 re Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry
- » Reference 14 re Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry
- » Reference 13 re Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry